Roth MKM analyst Scott Henry raised the firm’s price target on Journey Medical to $7 from $4 and keeps a Buy rating on the shares. The company’s Q2 results were at the high end of expectations as revenue benefited from rebounds to Qbrexza and Accutane and with the management continuing to cut costs with positive adjusted EBITDA appearing a near-term likelihood, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on DERM:
- Journey Medical Corporation Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
- DERM Upcoming Earnings Report: What to Expect?
- Journey Medical Corporation to Announce Second Quarter 2023 Financial Results on August 8, 2023
- Journey Medical Corporation to Announce Second Quarter 2023 Financial Results the Week of August 7, 2023
- Journey Medical achieved co-primary endpoints in MVOR-1, MVOR-2 studies